Nature Catalysis:利用磁力将药物直接输送到癌症组织,有望治愈癌症患者

2018-02-03 榕榕 来宝网

佐治亚大学的一个研究小组开发了一种非侵入性方法,利用磁力将药物直接输送到癌症组织,这种治疗方法可以显着减少化疗的毒副作用。

【基于磁性的药物递送系统显示出对癌症治疗的希望】佐治亚大学的一个研究小组开发了一种非侵入性方法,利用磁力将药物直接输送到癌症组织,这种治疗方法可以显着减少化疗的毒副作用。

UGA大学家庭与消费科学学院纳米结构材料实验室的研究生Andrey Zakharchenko说:“我们证明,我们可以在需要的地方提供抗癌药物,并且可以杀死癌细胞。

纽约UGA和克拉克森大学的研究人员首先创建了非常好的纳米颗粒,作为药物载体,其中一个载有药物的底物基质,另一个载有酶。

在施加相对较弱的磁场时,两个纳米颗粒合并,迫使在特定位置释放药物的反应。

通过控制相互作用的时机,研究人员可以确定药物的输送位置,从而预防化疗的副作用,如脱发或心脏毒性。

研究人员使用化疗药物和癌细胞进行了体外概念研究的证明。 Zakharchenko说,下一步将是开发一个动物模型。

美国乔治亚州纤维和聚合物科学教授Sergiy Minko表示:“使用静态磁场引起反应非常重要,因为它不会对身体构成威胁。” Sergiy MinkoFACS为纺织品,商品和室内装饰部门的乔治亚州电力学教授,属于艺术与科学学院化学系。

在以前的研究中,脉动磁场已经被用来传递药物,但是应用所产生的热量会破坏患者的健康细胞。

这篇文章出现在一月份的“自然催化”杂志上。

原始出处:

Andrey Zakharchenko, Nataliia Guz, Amine Mohamed Laradji,et al. Magnetic field remotely controlled selective biocatalysis. Nature Catalysisvolume 1, pages73–81 (2018), doi:10.1038/s41929-017-0003-3.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800064, encodeId=5a6a1800064eb, content=<a href='/topic/show?id=33a4e146430' target=_blank style='color:#2F92EE;'>#癌症组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71464, encryptionId=33a4e146430, topicName=癌症组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Jan 03 13:26:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882826, encodeId=e3cf188282654, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Feb 06 15:26:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782650, encodeId=3e971e826506d, content=<a href='/topic/show?id=a7c74152c9' target=_blank style='color:#2F92EE;'>#catalysis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4152, encryptionId=a7c74152c9, topicName=catalysis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 10 10:26:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289585, encodeId=252012895851a, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466043, encodeId=50921466043ee, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800064, encodeId=5a6a1800064eb, content=<a href='/topic/show?id=33a4e146430' target=_blank style='color:#2F92EE;'>#癌症组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71464, encryptionId=33a4e146430, topicName=癌症组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Jan 03 13:26:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882826, encodeId=e3cf188282654, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Feb 06 15:26:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782650, encodeId=3e971e826506d, content=<a href='/topic/show?id=a7c74152c9' target=_blank style='color:#2F92EE;'>#catalysis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4152, encryptionId=a7c74152c9, topicName=catalysis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 10 10:26:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289585, encodeId=252012895851a, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466043, encodeId=50921466043ee, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
    2018-02-06 一叶知秋
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800064, encodeId=5a6a1800064eb, content=<a href='/topic/show?id=33a4e146430' target=_blank style='color:#2F92EE;'>#癌症组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71464, encryptionId=33a4e146430, topicName=癌症组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Jan 03 13:26:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882826, encodeId=e3cf188282654, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Feb 06 15:26:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782650, encodeId=3e971e826506d, content=<a href='/topic/show?id=a7c74152c9' target=_blank style='color:#2F92EE;'>#catalysis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4152, encryptionId=a7c74152c9, topicName=catalysis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 10 10:26:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289585, encodeId=252012895851a, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466043, encodeId=50921466043ee, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800064, encodeId=5a6a1800064eb, content=<a href='/topic/show?id=33a4e146430' target=_blank style='color:#2F92EE;'>#癌症组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71464, encryptionId=33a4e146430, topicName=癌症组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Jan 03 13:26:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882826, encodeId=e3cf188282654, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Feb 06 15:26:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782650, encodeId=3e971e826506d, content=<a href='/topic/show?id=a7c74152c9' target=_blank style='color:#2F92EE;'>#catalysis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4152, encryptionId=a7c74152c9, topicName=catalysis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 10 10:26:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289585, encodeId=252012895851a, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466043, encodeId=50921466043ee, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1800064, encodeId=5a6a1800064eb, content=<a href='/topic/show?id=33a4e146430' target=_blank style='color:#2F92EE;'>#癌症组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71464, encryptionId=33a4e146430, topicName=癌症组织)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Jan 03 13:26:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882826, encodeId=e3cf188282654, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Feb 06 15:26:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782650, encodeId=3e971e826506d, content=<a href='/topic/show?id=a7c74152c9' target=_blank style='color:#2F92EE;'>#catalysis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4152, encryptionId=a7c74152c9, topicName=catalysis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Sep 10 10:26:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289585, encodeId=252012895851a, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466043, encodeId=50921466043ee, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Mon Feb 05 00:26:00 CST 2018, time=2018-02-05, status=1, ipAttribution=)]
    2018-02-05 bbjsj_1981

相关资讯

JAHA:癌症治疗“伤心”知多少

一旦人们得知自己患上了癌症,无异于五雷轰顶,不断研发的癌症治疗药物则被癌症患者视为救命稻草。殊不知,癌症治疗药物既能治病,也能致病,使用不当反而会危及患者的生命安全。其中,心血管并发症,如QT延长和危及生命的尖端扭转心律不齐,就在不断考验者肿瘤科医生的专业技能。 尽管QT延长不是心律不齐风险的完美标志物,但其已成为肿瘤学家公认的主要安全性标准。为接受癌症治疗的患者提供医疗的心脏病专家只有对与

Lancet:跨越 15 年,71 国近 3800 万癌症患者,18 种癌症各国全新 5 年生存率变化趋势发布,中国形势不容乐观

由美国癌症协会,瑞士癌症研究基金会,美国国家癌症研究所等机构赞助的 2000 - 2014 年全球癌症生存趋势监测计划(CONCORD 计划)第三阶段的数据发表在权威医学期刊《柳叶刀》杂志上。

丁香成为新一代超级食物,具备逆转糖尿病和癌症的潜力

丁香原产于印度尼西亚,是丁香树上的干花蕾,是人们在汤、炖肉、肉类、酱汁和米饭中使用的一种流行香料。他们的名字来源于拉丁文的clavus,意思是指甲,因为干丁香的形状类似指甲。人们已经在烹饪和传统医药中使用丁香很多年了,但直到最近,科学家才开始研究丁香对健康的潜在益处。

PNAS:电子烟也致癌,还是彻底戒了吧!

电子烟(E-cig)一直被推广为非致癌物和更安全的烟草替代品。然而,1月29日发表在《美国科学院院报》(PNAS)杂志上的最新研究表明,电子烟中的尼古丁会破坏DNA和抑制DNA修复,从而可能导致肺癌和膀胱癌以及心脏病。

BMJ:MD Anderson研究:慢性病占癌症发生、死亡影响因素的20-30%

MD Anderson癌症中心Tu教授等人就几种慢性病及相关标志物与癌症(发病率及死亡率)间的关系进行了前瞻性队列研究,相关结果发表于全球瞩目的四大医学期刊之一《BMJ》。

Nat Commun:瑞士研发癌症新疗法,“隐性病毒”疗法精准消除癌细胞!

来自苏黎世大学的科学家重新设计了一种用于癌症治疗的腺病毒。为了实现这一目标,他们开发了一种新的蛋白质屏蔽物,它可以隐藏病毒并保护它不被消灭。病毒表面的适配器使重组病毒能够特异性地感染肿瘤细胞。